Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study

The Lancet Child and Adolescent Health

Volumn 2, Issue 10, 2018, Pages 707-714

  Silverberg, Michael J ^a   Leyden, Wendy A ^a   Lam, Jennifer O ^a   Gregorich, Steven E ^b   Huchko, Megan J ^d   Kulasingam, Shalini ^e   Kuppermann, Miriam ^b,c   Smith McCune, Karen K ^c   Sawaya, George F ^b,c  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA IN SITU; ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTPATIENT CARE; RISK ASSESSMENT; SEXUALLY TRANSMITTED DISEASE; SMOKING; UNITED STATES; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; ADOLESCENT; AGE; IMMUNIZATION; PAPILLOMAVIRUS INFECTION; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 85054866942     PISSN: None     EISSN: 23524642     Source Type: Journal    
DOI: 10.1016/S2352-4642(18)30220-7     Document Type: Article

References (29)

1. Meites, E, Kempe, A, Markowitz, LE, Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 65 (2016), 1405–1408.
2. Drolet, M, Bénard, É Boily, M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
3. Heard, I, Tondeur, L, Arowas, L, et al. Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis 215 (2017), 757–763.
4. Hofstetter, AM, Ompad, DC, Stockwell, MS, Rosenthal, SL, Soren, K, Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr 170 (2016), 445–452.
5. Mahmud, SM, Kliewer, EV, Lambert, P, Bozat-Emre, S, Demers, AA, Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. J Clin Oncol 32 (2014), 438–443.
6. Merckx, M, Broeck, DV, Benoy, I, Depuydt, C, Weyers, S, Arbyn, M, Early effects of human papillomavirus vaccination in Belgium. Eur J Cancer Prev 24 (2015), 340–342.
7. Mollers, M, King, AJ, Knol, MJ, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: results from a longitudinal Dutch cohort study. Vaccine 33 (2015), 2678–2683.
8. Powell, SE, Hariri, S, Steinau, M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 31 (2012), 109–113.
9. Kim, J, Bell, C, Sun, M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ 188 (2016), E281–E288.
10. Sankaranarayanan, R, Prabhu, PR, Pawlita, M, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 17 (2016), 67–77.
11. Baldur-Felskov, B, Dehlendorff, C, Junge, J, Munk, C, Kjaer, SK, Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 25 (2014), 915–922.
12. Benard, VB, Castle, PE, Jenison, SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 3 (2016), 833–837.
13. Brotherton, JML, Fridman, M, May, CL, Chappell, G, Saville, AM, Gertig, DM, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377 (2011), 2085–2092.
14. Flagg, EW, Torrone, EA, Weinstock, H, Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007–2014. Am J Public Health 106 (2016), 2211–2218.
15. Hariri, S, Johnson, ML, Bennett, NM, et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 121 (2015), 2775–2781.
16. Niccolai, LM, Julian, PJ, Meek, JI, McBride, V, Hadler, JL, Sosa, LE, Declining rates of high-grade cervical lesions in young women in Connecticut, 2008–2011. Cancer Epidemiol Biomarkers Prev 22 (2013), 1446–1450.
17. Niccolai, LM, Meek, JI, Brackney, M, Hadler, JL, Sosa, LE, Weinberger, DM, Declines in human papillomavirus (HPV)–associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008–2015. Clinical Infectious Diseases 65 (2017), 884–889.
18. Hariri, S, Bennett, NM, Niccolai, LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine 33 (2015), 1608–1613.
19. Munoz, N, Kjaer, SK, Sigurdsson, K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102 (2010), 325–339.
20. Castellsague, X, Munoz, N, Pitisuttithum, P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer 105 (2011), 28–37.
21. Gertig, DM, Brotherton, JM, Budd, A, Drennan, K, Chappell, G, Saville, AM, Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 11 (2013), 1–12.
22. Pollock, KG, Kavanagh, K, Potts, A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111 (2014), 1824–1830.
23. Crowe, E, Pandeya, N, Brotherton, JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ, 348, 2014, g1458.
24. Brotherton, JML, Malloy, M, Budd, AC, Saville, M, Drennan, KT, Gertig, DM, Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res 1 (2015), 59–73.
25. Gordon, NP, Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2011 California Health Interview Survey. https://divisionofresearch.kaiserpermanente.org/projects/memberhealthsurvey/SiteCollectionDocuments/chis_non_kp_2011.pdf, June 19, 2015. (Accessed 22 March 2018)
26. Silverberg, MJ, Leyden, WA, Chi, A, et al. Human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol 131 (2018), 47–55.
27. Langholz, B, Case-control studies = odds ratios: blame the retrospective model. Epidemiology 21 (2010), 10–12.
28. Ozawa, N, Ito, K, Tase, T, Shibuya, D, Metoki, H, Yaegashi, N, Lower incidence of cervical intraepithelial neoplasia among young women with human papillomavirus vaccination in Miyagi, Japan. Tohoku J Exp Med 243 (2017), 329–334.
29. Bosch, FX, Robles, C, Diaz, M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13 (2016), 119–132.